株価の高値、安値、推移の概要Roche Holding
過去の株価
現在の株価	CHF 344.20
52週高値	CHF 375.80
52週安値	CHF 252.20
ベータ	0.35
1ヶ月の変化	-3.07%
3ヶ月変化	6.23%
1年変化	32.18%
3年間の変化	33.44%
5年間の変化	0.79%
IPOからの変化	1,218.77%

Recent updates

ナラティブ更新 • Aug 24

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

Analysts have nudged their fair value estimate for Roche Holding to CHF 267.89 from CHF 260.11, citing a mix of higher assumed revenue growth, a slightly adjusted discount rate, modestly lower profit margin expectations, and a marginally higher future P/E. Analyst Commentary Recent Street research around Roche Holding offers a mixed picture for investors, with some firms highlighting potential growth drivers while others flag valuation and execution risks.

ナラティブ更新 • Aug 10

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Analysts have lifted their fair value estimate for Roche Holding to CHF 370.31 from CHF 359.22, citing a combination of visible growth, incremental pipeline contributions including giredestrant, and recent partnership activity. They view these factors as supporting revenue growth assumptions and profit margin resilience, despite a slightly higher discount rate and a modestly lower future P/E multiple.

分析記事 • Jul 31

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investors signalled that they were pleased with Roche Holding AG's ( VTX:ROP ) most recent earnings report. According...

ナラティブ更新 • Jul 27

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analysts lifted their fair value estimate for Roche Holding, implying a new price target of about CHF 260. They incorporated updated assumptions on revenue growth, margins and P/E following a series of partnership-focused research notes around the company's Nurix collaboration and a recent HSBC rating change.

分析記事 • Jul 27

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Investors in Roche Holding AG ( VTX:ROP ) had a good week, as its shares rose 7.1% to close at CHF355 following the...

ナラティブ更新 • Jul 10

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Analysts have modestly lifted their fair value estimate for Roche Holding to CHF 359.22 from CHF 352.00, citing updated assumptions around revenue growth, profit margins and future P/E, along with mixed but generally constructive readthroughs from recent pipeline and partnership research. Analyst Commentary Recent Street research around Roche Holding points to a mixed but constructive setup, with optimism around specific products and partnerships balanced by more cautious views on the risk and timing of future growth and execution.

ナラティブ更新 • Jun 26

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Analysts have updated their fair value estimate for Roche Holding to CHF 253.81 from CHF 295.00, reflecting refreshed assumptions on revenue growth, margins, and future P/E multiples in light of recent co-development agreements with partners such as Nurix Therapeutics. Analyst Commentary Recent Street research around Roche Holding and its partners gives you a mixed picture, with enthusiasm for the co-development agreements alongside more cautious voices highlighting execution and valuation risks.

新しいナラティブ • May 12

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Investment Memo – Roche Holding AG (Pharmaceutical Division / “Roche Pharma”) 1. Executive Summary Roche is a leading global pharmaceutical and diagnostics company with a strong focus on oncology, immunology, neuroscience, and rare diseases.

新しいナラティブ • Apr 19

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Catalysts About Roche Holding Roche is a global healthcare company focused on pharmaceuticals and diagnostics across oncology, neurology, immunology, ophthalmology and cardiometabolic diseases. What are the underlying business or industry changes driving this perspective?

新しいナラティブ • Apr 04

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Catalysts About Roche Holding Roche Holding is a global healthcare company with large pharmaceutical and diagnostics businesses focused on prescription medicines, biologics and lab testing solutions. What are the underlying business or industry changes driving this perspective?

新しいナラティブ • Mar 21

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Catalysts About Roche Holding Roche Holding is a global healthcare group focused on pharmaceuticals and diagnostics, with a large late stage pipeline and extensive manufacturing and R&D infrastructure. What are the underlying business or industry changes driving this perspective?

株主還元

	ROP	CH Pharmaceuticals	CH 市場
7D	-2.7%	-5.8%	-2.8%
1Y	32.2%	23.0%	11.4%

業界別リターン: ROP過去 1 年間で23 % の収益を上げたSwiss Pharmaceuticals業界を上回りました。

リターン対市場: ROP過去 1 年間で11.4 % の収益を上げたSwiss市場を上回りました。

価格変動

Is ROP's price volatile compared to industry and market?
ROP volatility
ROP Average Weekly Movement	3.4%
Pharmaceuticals Industry Average Movement	4.5%
Market Average Movement	3.9%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	2.0%

安定した株価: ROP 、 Swiss市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: ROPの週次ボラティリティ ( 3% ) は過去 1 年間安定しています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1896	103,249	Thomas Schinecker	www.roche.com

ロシュ・ホールディングAGは、欧州、北米、中南米、アジア、アフリカ、オーストラリア、ニュージーランドで医薬品および診断薬事業を展開している。貧血、血液・固形腫瘍、皮膚科、血液内科、感染症、炎症・自己免疫疾患、神経疾患、眼科、呼吸器疾患、移植などの治療分野において医薬品ソリューションを提供している。また、がん、糖尿病、Covid-19、肝炎、ヒトパピローマウイルスなど様々な疾患の診断のための体外検査、診断機器、デジタルヘルスソリューションも提供している。同社は1896年に設立され、スイスのバーゼルに本社を置いている。

Roche Holding AG 基礎のまとめ

Roche Holding の収益と売上を時価総額と比較するとどうか。
ROP 基礎統計学
時価総額	CHF 275.14b
収益（TTM）	CHF 12.34b
売上高(TTM)	CHF 62.96b

22.2x

PER（株価収益率

4.4x

P/Sレシオ

ROP は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ROP 損益計算書（TTM）
収益	CHF 62.96b
売上原価	CHF 16.26b
売上総利益	CHF 46.70b
その他の費用	CHF 34.35b
収益	CHF 12.34b

直近の収益報告

Jun 30, 2026

次回決算日

Oct 22, 2026

一株当たり利益（EPS）	15.49
グロス・マージン	74.17%
純利益率	19.60%
有利子負債／自己資本比率	86.6%

ROP の長期的なパフォーマンスは？

過去の実績と比較を見る

配当金

2.8%

現在の配当利回り

63%

配当性向

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/09/14 11:39
終値	2026/09/11 00:00
収益	2026/06/30
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築したご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Roche Holding AG 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。45

アナリスト	機関
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Mark Purcell	Barclays

Roche Holding（ROP）株式概要

報酬

リスク分析

Analyst Price Targets

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Analyst Narratives

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Roche Holding AG 競合他社

Novartis

Galderma Group

Sandoz Group

Dottikon ES Holding

価格と性能

最新ニュース

Roche Advances Global Plans After Tam-Peli Lung Cancer Trial Shows Survival Benefit

FDA Priority Review Advances Roche Enspryng Bid for First MOGAD Therapy Approval

Roche Receives U.S. FDA Priority Review for Enspryng for MOGAD

Roche to Launch Phase 1 Combination Trial With Treeline in B-Cell Lymphomas

New minor risk - Dividend sustainability

Roche Presents Two-Year Results From The SALWEEN Study Of Vabysmo In Polypoidal Choroidal Vasculopathy

Recent updates

Roche Advances Global Plans After Tam-Peli Lung Cancer Trial Shows Survival Benefit

FDA Priority Review Advances Roche Enspryng Bid for First MOGAD Therapy Approval

Roche Receives U.S. FDA Priority Review for Enspryng for MOGAD

Roche to Launch Phase 1 Combination Trial With Treeline in B-Cell Lymphomas

New minor risk - Dividend sustainability

Roche Presents Two-Year Results From The SALWEEN Study Of Vabysmo In Polypoidal Choroidal Vasculopathy

Roche Receives FDA Approval For Companion Diagnostic Tests to Identify Patients With HER2-Positive Metastatic Gastroesophageal Adenocarcinoma Eligible For ZIIHERA

Roche Licenses Hanmi Obesity Drug Candidate in $2.3 Billion Deal With Genentech

Roche Receives FDA Clearance For Elecsys Ptau217 Blood Test For Alzheimer’s Disease Assessment

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

Genentech to Expand Hillsboro Facility With $750 Million Investment for Advanced Injectables

Genentech Reaches Construction Milestone for $2 Billion North Carolina Biomanufacturing Facility

ChemoMetec and Roche Team Up on Cedex Bio Analyzer Integration Collaboration

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Roche Holding Teams With Evexta Bio for Phase 1b Breast Cancer Drug Trial

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Roche Gains FDA Clearance for cobas BV/CV Molecular Vaginitis Diagnostic

First half 2026 earnings released

CHMP Backs EU Approval for Susvimo Continuous Eye Treatment in Roche Milestone

Roche Receives Positive CHMP Recommendation For Susvimo For Neovascular Age-Related Macular Degeneration

Roche Receives FDA Clearance For The Cobas BV/CV Assay Enabling Fast And Highly Accurate Vaginitis Diagnosis

Roche Names Dan Malarek CEO of Diagnostics North America as Leadership Team Shifts

FDA Sets Priority Review for Roche’s Gazyva in Rare Kidney Disease Therapy Decision

Roche Announces FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Primary Membranous Nephropathy

Roche Unveils First Fully Automated HDV Test for Severe Hepatitis Detection and Monitoring

Roche Introduces Cobas Hepatitis D Virus Test for Use on Cobas 5800/6800/8800 Systems

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Roche Receives CE Mark for Automated Tuberculosis Blood Test Across Europe

Roche Presents New Data in Alzheimer’S Disease Portfolio At Aaic 2026

Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer

FDA Accepts Priority Review for Roche Enspryng in Thyroid Eye Disease Expansion

Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease

Roche Announces Launch Of AXELIOS 1 Sequencing Platform

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Roche Backs Orano Med to Advance Lead-212 Radiopharma Cancer Therapies

Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma

Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer

Roche Expands Cancer Diagnostics and Awaits FDA Decision on Tecentriq for Colon Cancer

Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer

Roche Advances Breast Cancer Pipeline With FDA Review for Giredestrant and Companion Diagnostic Approval

Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer

Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi (Inavolisib) in Combination with Palbociclib and Fulvestrant

Roche Launches the Liver Disease Panel Suite of Certified Algorithms to Support Chronic Liver Disease Management

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Roche Receives CE Mark For Elecsys Ptau217 Blood Test For Alzheimer’S Disease Pathology

Roche Holding AG (SWX:ROP) entered into a definitive merger agreement to acquire PathAI, Inc. for $1.1 billion.

Roche Showcases Ophthalmology Portfolio At Arvo 2026

Roche Announces FDA Acceptance of Application for Gazyva Gazyvaro for Treatment of Systemic Lupus Erythematosus

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership